A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study, Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% to CABTREO (Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide) Topical Gel and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris.

To demonstrate the efficacy, therapeutic equivalence and safety of Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel in the treatment of acne vulgaris.

开始日期2024-05-13

申办/合作机构

Taro Pharmaceuticals U.S.A., Inc.

CTR20230701

/ Active, not recruiting临床3期

评估他扎克林乳膏治疗中度寻常性痤疮的安全性和有效性的多中心、随机、单盲、阳性药平行对照的Ⅲ期临床试验

本试验为Ⅲ期临床试验，旨在探索他扎克林乳膏对比他扎罗汀乳膏、克林霉素磷酸酯凝胶单独用药治疗中度寻常性痤疮的有效性和安全性。

开始日期2023-08-10

申办/合作机构

江苏知原药业股份有限公司

[+1]

NCT04892706

/ Completed临床2期

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% Adapalene/2.5% BPO), in the Treatment of Acne Vulgaris

The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.

开始日期2021-06-11

申办/合作机构

Bausch Health Americas, Inc.

100 项与 RARs x 50S subunit 相关的临床结果

登录后查看更多信息

100 项与 RARs x 50S subunit 相关的转化医学

登录后查看更多信息

0 项与 RARs x 50S subunit 相关的专利（医药）

登录后查看更多信息